This leads to steadier energy levels and better metabolic stability (NIH)
Related article: Diabetes risk factors Ischaemic optic neuropathy: A 2026 study looked at FDA adverse event reporting from 2017 2024 for GLP-1 medications
References 1 KFF, November 2025 2 KFF, November 2025 3 Beth Israel Deaconess Medical Center, November 2024 4 Baylor Scott & White Health, May 2026 5 Tufts Medicine, August 2025 6 Cornell Chronicle, September 2025 7 Curion, March 2026 8 WSJ, GLP-1 Users Are Taking a Bite Out of the Restaurant Business, May 13, 2026 9 Northwestern Now, November 2024 10 Northwestern Now, November 2024 For more information, visit harmelin.com, or connect with us on LinkedIn or Facebook.
These changes are likely due in part to glucagon receptor activation, which promotes lipid oxidation and decreases lipogenesis in the liver